Ipsen

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, April 4, 2024
MAA, ACLF, Primary biliary cholangitis, Patient, Research, Ipsen, Placebo, EMA, Bank statement, Marketing, PBC, FDA, EF, Pharmaceutical industry

“A remarkable milestone was reached by GENFIT in 2023 with the announcement of positive topline data for our Phase 3 ELATIVE® trial evaluating elafibranor in Primary Biliary Cholangitis.

Key Points: 
  • “A remarkable milestone was reached by GENFIT in 2023 with the announcement of positive topline data for our Phase 3 ELATIVE® trial evaluating elafibranor in Primary Biliary Cholangitis.
  • This was followed by another asset acquisition in July 2023, where GENFIT licensed the exclusive worldwide rights of CLM-022, a potential first-in-class inflammasome inhibitor, from Celloram.
  • IND was in effect as of April 17, 2023 and the first patient was randomized in the UNVEIL-IT® Phase 2 trial in July 2023.
  • GENFIT equally obtained a “Prime status” label by ISS ESG, upgrading its corporate rating from C to C+.

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

Retrieved on: 
Thursday, March 21, 2024
University, Sanofi, Therapeutic index, Growth, GSK plc, Rotman School of Management, Merck Serono, Immunotherapy, Partnership, Patient, SAN, Ipsen, Merck, Cancer, Faculty, Society, TU Dresden, Therapy, Institute of technology, SITC, University of Florida

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.
  • “We are excited to welcome Zhen to our board,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX.
  • Dr. Su is currently chief executive officer of Marengo Therapeutics and a member of its Board of Directors.
  • Dr. Su also serves on the board of directors of Karyopharm Therapeutics and as the funding chairperson for the biotech committee of the Society for Immunotherapy of Cancer (SITC).

MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neurology, Growth, Survival, Doctor of Pharmacy, Microbiota, Maat, Patient, Ipsen, Cancer, MET, Pharmaceutical industry

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced the appointment of Jonathan Chriqui, PharmD, as Chief Business Officer and member of the executive management team.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced the appointment of Jonathan Chriqui, PharmD, as Chief Business Officer and member of the executive management team.
  • Jonathan Chriqui will be responsible for MaaT Pharma’s business development and partnering strategies along with promoting MaaT Pharma's innovations within the microbiome industry.
  • MaaT Pharma is now poised to propel its lead asset, MaaT013, into the next phase of development and prepare for its commercial launch,” said Hervé Affagard, Chief Executive Officer and co-founder of MaaT Pharma.
  • I look forward to contributing to the advancement of MaaT013 towards the market and supporting the company’s mission of providing new treatment options for patients with cancer,” shared Jonathan Chriqui, Chief Business Officer at MaaT Pharma.

Quotient Sciences Strengthens Its Top Team with Three New Appointments

Retrieved on: 
Monday, March 18, 2024
Quotient, Patient, Ipsen, Business development, Senior, Drug development, Ciarán, Translation, Novasep, Consultant, Marketing, Management

NOTTINGHAM, England, March 18, 2024 /PRNewswire/ -- Drug development and manufacturing accelerator Quotient Sciences has announced major changes to its commercial and scientific executive leadership team, strengthening its position as a global leader in the sector.

Key Points: 
  • Andrew will lead the team of Drug Development Consultants and Scientific Research Fellows to grow Quotient Sciences' global scientific expertise and recognition.
  • During his eight years with Quotient Sciences, Andrew has held various scientific leadership positions, most recently as Senior Vice President, Pharmaceutical Development.
  • He was Head of Business Development in Europe for Cyprotex (an Evotec company) before joining Quotient Sciences.
  • Eric Bironneau has joined the company as Chief Business Officer, with responsibility for Quotient Sciences' commercial organization across drug substance, drug product, and Translational Pharmaceutics® commercial lines, as well as for Quotient Sciences' strategic partnerships.

Quotient Sciences Strengthens Its Top Team with Three New Appointments

Retrieved on: 
Monday, March 18, 2024
Quotient, Patient, Ipsen, Business development, Senior, Drug development, Ciarán, Translation, Novasep, Consultant, Marketing, Management

NOTTINGHAM, England, March 18, 2024 /PRNewswire/ -- Drug development and manufacturing accelerator Quotient Sciences has announced major changes to its commercial and scientific executive leadership team, strengthening its position as a global leader in the sector.

Key Points: 
  • Andrew will lead the team of Drug Development Consultants and Scientific Research Fellows to grow Quotient Sciences' global scientific expertise and recognition.
  • During his eight years with Quotient Sciences, Andrew has held various scientific leadership positions, most recently as Senior Vice President, Pharmaceutical Development.
  • He was Head of Business Development in Europe for Cyprotex (an Evotec company) before joining Quotient Sciences.
  • Eric Bironneau has joined the company as Chief Business Officer, with responsibility for Quotient Sciences' commercial organization across drug substance, drug product, and Translational Pharmaceutics® commercial lines, as well as for Quotient Sciences' strategic partnerships.

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

Retrieved on: 
Monday, February 26, 2024
Sildenafil, Therapy, Pfizer, RSU, Marketing, Common stock, Public health, IRON, Ascending cholangitis, Lumacaftor/ivacaftor, Ipsen, Brown University, Vertex Pharmaceuticals, Patient, Pregabalin, Public, MPH, Policy, Pharmaceutical industry

WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Pamela Stephenson, MPH as the company’s Chief Commercial Officer.

Key Points: 
  • WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Pamela Stephenson, MPH as the company’s Chief Commercial Officer.
  • “We are delighted to welcome an accomplished leader such as Pamela to Disc, where her breadth of commercial experience and acumen will be instrumental as the company continues to grow,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc.
  • Most recently, she served as the Chief Commercial Officer of Albireo, which was acquired by Ipsen, spearheading the successful launch of Bylvay for a rare cholestatic liver disease.
  • The Inducement Award was approved by Disc’s Board of Directors (the “Board”), including a majority of the independent directors serving on the Board.

Neurenati Therapeutics Concludes a 1.2 Million $ Seed Financing Round to Develop NEU-001 as a Promising Therapy for Hirschsprung Disease

Retrieved on: 
Thursday, February 29, 2024
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Investigational New Drug, Enterocolitis, Inflammatory Bowel Diseases, Drug development, UQAM, Pediatrics, Life, Ipsen, Therapy, Patient, Intellectual property, IND, Gastroenterology, Partnership, Pharmaceutical industry

Neurenati Therapeutics is delighted to announce the successful closing of its seed funding round, securing 1.2 million $ from Genson Capital, on the 2024 Rare Disease Day.

Key Points: 
  • Neurenati Therapeutics is delighted to announce the successful closing of its seed funding round, securing 1.2 million $ from Genson Capital, on the 2024 Rare Disease Day.
  • Neurenati, a Québec-based biotech company, focuses on the development of various rare diseases therapies, including pediatric conditions.
  • Maxime Ranger, President and CEO of Neurenati Therapeutics commented, “Currently, surgery remains the only option to newborns with HSCR.
  • As fourth member of the Board, he joins Rodolphe Soret (cofounder), Benoit Doré (Axelys), and Maxime Ranger (Neurenati).

SHE Media's Second Annual Co-Lab at SXSW® Elevating Leading Voices in Women's Health to the Mainstage

Retrieved on: 
Friday, March 8, 2024
Narrative, SXSW, The New York Times, Media, AI, Colorectal cancer, Health, IVF, American Medical Association, Commerce, Risk, Impossible, Ipsen, Entrepreneurship, Patient, Yoga, Cardiovascular disease, Medtronic, Heart, Host, Science, Journalist, Artificial intelligence, Consciousness, SHE Media

AUSTIN, Texas, March 8, 2024 /PRNewswire/ -- Today, SHE Media, a mission-driven media company, announced its full agenda and latest speaker lineup for the Co-Lab: Whole Life Health at South by Southwest® (SXSW®). The highly anticipated activation, in its second year, will take place March 9, 10 and 11 in Downtown Austin at 206 E 4th St. Attendees will hear from experts, advocates, and thought leaders as they share both the science and stories of women's whole life health including the latest innovations and how technology is revolutionizing healthcare. Doors will open daily at 9am and close at 5pm with panel discussions and fireside chats programmed throughout the day. Full agenda details and updates can be found here.

Key Points: 
  • Doors will open daily at 9am and close at 5pm with panel discussions and fireside chats programmed throughout the day.
  • The Co-Lab at SXSW marks the one-year anniversary of launching Flow Space , SHE Media's proprietary digital and live media platform providing content, community, and commerce in service of women's health.
  • Learn how we can better care for our hearts, including how symptoms differ in women, preventative measures and innovations that can reduce risk.
  • plusOne® Sexual Wellness in Full Bloom | Attendees can celebrate sexual wellness by stopping by the plusOne® flower cart to receive a tote and Rose Arouser.

Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors

Retrieved on: 
Thursday, February 8, 2024
Wheaton College, Neoplasm, Research, Harvard University, Genetics, Patient, Head, IPO, Chemistry, Doctor of Philosophy, AP3, Senior counsel, Applied Genetic Technologies Corporation, Ipsen, Therapy, ACRV, Medicine, Proteomics, Suffolk University Law School, Biology, IP, Teva Pharmaceuticals, Management

“We are excited to welcome Ivana to our board of directors,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.

Key Points: 
  • “We are excited to welcome Ivana to our board of directors,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • Under her strong leadership, Vigil has evolved from inception through IPO, to an organization with two clinical-stage development programs.
  • Dr. Magovčević-Liebisch has served on the Board of Directors of Absci, Aeglea Therapeutics and Applied Genetic Technologies Corporation.
  • I look forward to working with Peter, the board, and the executive team to develop multiple promising drug candidates to improve patient lives.”

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Retrieved on: 
Thursday, February 8, 2024
GLT, Growth, Certification, Prostate cancer, Palovarotene, Statute, Alagille syndrome, Primary biliary cholangitis, PDAC, Patient, FDA, FOP, Cabozantinib, Food, PBC, Botulinum toxin, Irinotecan, Ipsen, Phase, Acquisition, Environment, Albireo, Bank statement, Webcast, Carbon accounting, Core, Woman, Pharmaceutical industry

Ipsen ended the year with net cash of €65.1m, driven by solid free cash-flow generation of €710.9m.

Key Points: 
  • Ipsen ended the year with net cash of €65.1m, driven by solid free cash-flow generation of €710.9m.
  • Ipsen anticipates four commercial launches in 2024, following regulatory decisions for Onivyde in 1L PDAC in the U.S (H1), elafibranor in second-line PBC in the U.S. (H1) and in the E.U.
  • Ipsen has set the following financial guidance for FY 2024, which excludes any impact from potential late-stage external-innovation transactions:
    Total-sales growth greater than 6.0%, at constant currency.
  • The performance shown in this announcement covers the twelve-month period to 31 December 2023 (FY 2023) and the three-month period to 31 December 2023 (Q4 2023), compared to the twelve-month period to 31 December 2022 (FY 2022) and the three-month period to 31 December 2022 (Q4 2022), respectively, unless stated otherwise.